Key Highlights

  • 11.73% is the indicated pre-market gain for Faeth Therapeutics, Inc. (NASDAQ:FTH) on November 18, 2026, lifting the price to USD 10.10 from a calculated prior close of USD 9.04, a calculated USD 1.06 move.
  • 174.8 million USD was cash, cash equivalents and marketable securities at September 30, 2026, compared with USD 186.4 million at June 30, 2026 and USD 21.2 million at December 31, 2025.
  • 20.4 million USD was the third-quarter 2026 net loss, or USD 0.79 per share, versus USD 4.6 million or USD 3.62 per share a year earlier, on research expense of USD 11.7 million.
  • 2 programs anchor the pipeline: the Phase 2 PIK-201 trial of PIKTOR in second-line advanced endometrial cancer, with topline data guided by year-end 2026, and the Phase 1b/2 PIK-101 breast cancer trial.

What Moved Faeth Therapeutics, Inc. (NASDAQ:FTH) in Pre-Market Trading on November 18, 2026 (+USD 1.06, +11.73%)

The indicated pre-market price for Faeth Therapeutics, Inc. (NASDAQ:FTH) is USD 10.10 on November 18, 2026, a pre-market move of +11.73%. The calculated prior close is USD 9.04 (USD 10.10 divided by 1.1173), and the calculated USD move is +USD 1.06. The indicated price is about 48.0% below the USD 19.44 level recorded on October 19, 2026 (calculated). A corroborated market Capitalization and pre-market Volume were not found.

The Rationale: Clinical Catalyst Path for PIKTOR at Faeth Therapeutics, Inc. (NASDAQ:FTH)

No catalyst dated November 18, 2026 was identified in published coverage. As background, the company, formerly Sensei Biotherapeutics and renamed in June 2026, completed a combination with a concurrent USD 200 million private placement. Published coverage dated November 9, 2026 carried a headline on positive preliminary Phase 2 topline results from PIK-201, though details were not corroborated here. Chief executive Anand Parikh said the company looks forward to reading out topline data from PIK-201 by year-end. Initial PIK-101 data are expected in 2027. As general context, clinical-stage shares often move on trial news and sector sentiment.

Valuation, Liquidity and Risks for Faeth Therapeutics, Inc. (NASDAQ:FTH)

Third-quarter Research and Development expense rose to USD 11.7 million from USD 2.5 million, and general and administrative expense rose to USD 10.4 million from USD 2.3 million on personnel and legal costs. Weighted-average shares were 25,840,555 against 1,261,290 a year earlier, reflecting the combination. Cash fell by USD 11.6 million from the second quarter (calculated). The company has no product revenue, and its value depends on trial outcomes, financing and regulatory progress. Efficacy, safety and timing risks are significant, and a trial setback could weigh heavily on a single-lead-program company.

Where Things Stand

Faeth Therapeutics, Inc. (NASDAQ:FTH) is indicated up 11.73% in pre-market trading on November 18, 2026, at USD 10.10, a calculated USD 1.06 above a prior close of USD 9.04. No catalyst dated today was identified in published coverage. At September 30, 2026 the clinical-stage company held USD 174.8 million of cash and securities and reported a third-quarter net loss of USD 20.4 million. Topline data from the Phase 2 PIK-201 endometrial cancer trial are guided by year-end 2026. Trial risk, cash burn and thin pre-market liquidity are key considerations, pre-market moves can reverse at the 9:30 a.m. ET open, and this is not Investment advice.